La vendita allo scoperto per Easterly Government Props dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Easterly Government Props. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Easterly Government Props (NYSE:DEA) Azioni, Report sulle vendite allo scoperto

Easterly Government Props

Easterly Government Properties Inc is a real estate investment trust. It is engaged in the acquisition, development, and management of Class A commercial properties that are leased to U.S. government agencies. The company generates all its revenue by leasing its properties to such agencies.

News

Dividends

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CLPR

Scopri le 3 azioni immobiliari con dividendi sopra il 7% consigliate dagli analisti di Wall Street per settembre.

3 azioni con dividendi sopra il 7% consigliate da Wall Street

Scopri i 3 migliori titoli immobiliari con dividendi oltre il 7% consigliati da Wall Street per investimenti redditizi.

3 titoli immobiliari con dividendi superiori al 7% consigliati da Wall Street

Easterly Government Properties, Inc. Common Stock

Easterly Government Properties Inc

DEAPcoin

DEALERADVANCE INC NEW by DealerAdvance, Inc.

DealerAdvance Inc

DEAR CASHMERE HOLDING CO by Dear Cashmere Holding Co.

Dear Cashmere Holding Co

Guidance
This guidance is forward-looking and reflects management's view of current and future market conditions. The Company's actual results may differ materially from this guidance.
Outlook for the 12 Months Ending December 31, 2024
The Company is maintaining its guidance for full-year 2024 Core FFO per share on a fully diluted basis at a range of $1.15 - $1.17.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">Low</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="2" rowspan="1">High</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net income (loss) per share – fully diluted basis</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">0.22</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.24</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Plus: Company's share of real estate depreciation and amortization</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">0.92</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.92</td>
</tr>
<tr>
<td colspan="1" rowspan="1">FFO per share – fully diluted basis</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1.14</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1.16</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Plus: Company's share of depreciation of non-real estate assets</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">0.01</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0.01</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Core FFO per share – fully diluted basis</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$</td>
<td colspan="1" rowspan="1">1.15</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1.17</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Earnings

Guidance

Easterly Government Properties Reaffirms Its Guidance For 2024 Core FFO per share of $1.15 - $1.17 Vs. $1.15 Est.

Easterly Government Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.29 by 3.45 percent. This is a 3.45 percent increase over earnings of $0.29 per share from the same period last year. The company reported quarterly sales of $74.781 million which missed the analyst consensus estimate of $76.703 million by 2.51 percent. This is a 3.84 percent increase over sales of $72.014 million the same period last year.

Earnings Beats

Earnings Misses

Easterly Government Props Q3 2024 FFO $0.30 Beats $0.29 Estimate, Sales $74.781M Miss $76.703M Estimate

A legal dispute has erupted in Allen, Texas, where cannabis shop owners and their advocates are taking a stand against local and federal law enforcement, claiming their rights were violated during <a href="https://www.benzinga.com/markets/cannabis/24/05/38826163/freedoms-just-another-word-for-losing-2-000-cannabis-plants-in-maine-police-raid">recent police raids. </a>
This lawsuit, filed by attorney David Sergi on Oct. 24, represents Sabhie Khan, a manager of Allen Smoke and Vape, and members of the Hemp Industry Leaders of Texas, following an August raid led by the Allen Police Department with the support of the U.S. Drug Enforcement Administration (DEA).
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/10/41521360/8b-market-on-the-brink-texas-senator-calls-it-uncontrollable-proposes-erasing-hemp">$8B Market On The Brink: Texas Senator Calls It &#8216;Uncontrollable,&#8217; Proposes Erasing Hemp</a>
Sergi condemned the raids as "fishing expeditions," saying "the DEA attempted to intimidate and bully these family businesses selling legal hemp," Lonestar Live <a href="https://www.lonestarlive.com/news/2024/10/cannabis-lawyer-claims-dea-tried-to-intimidate-and-bully-texas-smoke-shop-owners-in-new-lawsuit.html">reported</a>.
He contends that law enforcement's actions crossed a line, disregarding Texas&#8217;s hemp regulations and constitutional protections. Under Texas law, cannabis products with 0.3% delta-9 THC or less qualify as hemp, making them lawful within the state.
<h3 class="wp-block-heading">Raids And Arrests Spark Lawsuit</h3>
The incident that sparked the lawsuit occurred on Aug. 27, when Allen Police, collaborating with federal agencies, searched several shops, arresting Khan. The lawsuit alleges he was charged with a second-degree felony for "manufacturing a controlled substance" despite the seized products meeting Texas's legal definition of hemp.
According to Sergi, Khan, who is 70, was jailed for two days, "shackled in a jail cell without bond," despite his business being in compliance with state hemp laws. Sergi criticized the enforcement agencies' handling of Khan's case, saying they treated him "like the kingpin of a drug cartel, despite hemp being legal."
The plaintiffs argue that their Fourth, Fifth, Eighth, and 14th Amendment rights were breached in the process, naming the city of Allen, the Allen Police Department, Police Chief Steve Dye, Collin County Sheriff Jim Skinner and the DEA in the lawsuit. These amendments offer protections against unreasonable searches, self-incrimination, and cruel punishment, as well as guaranteeing due process.
<h3 class="wp-block-heading">Legal Battles And Disputed Testing Methods</h3>
The trouble began in May when Allen police allegedly sent notices to several CBD and vape shops, accusing them of selling "illegal THC products." The lawsuit claims the DEA followed suit in June, issuing subpoenas to Khan and other business owners, demanding sensitive personal and business data.
A federal judge issued a temporary stay on these subpoenas in July, questioning their legitimacy. However, the lawsuit alleges that the DEA sidestepped this judicial halt by engaging the Allen Police Department, who executed search warrants under allegedly flawed "questionable laboratory testing methods and standards" that could not differentiate between delta-9 THC and other legal cannabinoids in the products.
Sergi contends that these actions led to the seizure of approximately $8,000 to $10,000 worth of "legal inventory," with much of it being delta-8, THCa, and THCP products, all of which had certificates of analysis, a legal requirement for hemp products in Texas. 
Additionally, officers allegedly confiscated computers, phones and storage devices from Khan's shop, significantly impacting his business operations.
<h3 class="wp-block-heading">Calls For Legal Protections And Industry Standards</h3>
Khan and his fellow plaintiffs are not only seeking the immediate return of seized inventory and compensation for damages but are also requesting a permanent injunction to protect their businesses from future "unlawful actions." 
The lawsuit demands that any future testing on hemp products employ high-performance liquid chromatography (HPLC) to ensure compliance with Texas's legal standards, especially concerning the preservation of THCa, which Texas law treats differently from delta-9 THC.
The Allen Police Department has yet to issue a public response, citing "pending litigation." The outcome of this lawsuit could significantly impact Texas's hemp industry, as Khan and other business owners advocate for greater legal clarity and protections, insisting on their right to operate without undue interference from law enforcement.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/10/41198379/texas-hemp-industry-fights-delta-8-thc-ban-as-supreme-court-decision-looms">Texas Hemp Industry Fights Delta-8 THC Ban As Supreme Court Decision Looms</a></li>
</ul>
Cover image made with AI.

Cannabis

Legal

Texas Smoke Shop Owners Sue DEA Over 'Intimidation And Bullying' Tactics In Raid Of Legal Retail Store

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>)</h3>
<ul>
<li>Dividend Yield: 7.64%</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and raised the price target from $13 to $14 on Aug. 29. This analyst has an accuracy rate of 71%.</li>
<li>RBC Capital analyst Michael Leithead Carroll downgraded the stock from Sector Perform to Underperform and cut the price target from $15 to $13 on Aug. 16, 2023. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: Easterly Government Properties will release its third quarter 2024 financial results on Nov. 5.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1">latest DEA news.</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091804/image-256.png" alt="" class="wp-image-614448" style="width:746px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091804/image-256.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091804/image-256-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091804/image-256-768x705.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<h3 class="wp-block-heading">EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>)</h3>
<ul>
<li>Dividend Yield: 7.26%</li>
<li>JP Morgan analyst Anthony Paolone maintained an Overweight rating and raised the price target from $48 to $51 on Sept. 9. This analyst has an accuracy rate of 66%.</li>
<li>Truist Securities analyst Ki Bin Kim maintained a Hold rating and boosted the price target from $44 to $46 on Aug. 16. This analyst has an accuracy rate of 69%.</li>
<li>Recent News: EPR Properties will release its third quarter 2024 financial results after closing bell on Wednesday, Oct. 30.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1">latest EPR news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="812" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091839/image-257.png" alt="" class="wp-image-614450" style="width:735px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091839/image-257.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091839/image-257-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091839/image-257-768x688.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">OUTFRONT Media Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUT#NYSE">OUT</a>)</h3>
<ul>
<li>Dividend Yield: 6.46%</li>
<li>JP Morgan analyst Richard Choe maintained a Neutral rating and raised the price target from $17 to $18 on July 31. This analyst has an accuracy rate of 62%.</li>
<li>TD Cowen analyst Lance Vitanza initiated coverage on the stock a Hold rating with a price target of $16 on July 16. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: OUTFRONT Media will report results for the fiscal quarter ended Sept. 30, after the market closes on Tuesday, Nov. 5.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1">trend in OUT stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent102524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="830" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091913/image-258.png" alt="" class="wp-image-614453" style="width:700px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091913/image-258.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091913/image-258-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/25091913/image-258-768x699.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41528323/jim-cramer-says-hold-on-to-palantir-let-them-walk-it-up-warns-that-travere-therapeutics-is-losing-a">Jim Cramer Says &#8216;Hold On&#8217; To Palantir, &#8216;Let Them Walk It Up&#8217;; Warns That Travere Therapeutics Is Losing A &#8216;Ton Of Money&#8217;</a></li>
</ul>

Wall Street's Most Accurate Analysts Give Their Take On 3 Real Estate Stocks Delivering High-Dividend Yields

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/10/16/final-trades-transdigm-easterly-government-booz-allen-and-oneok.html">Halftime Report Final Trades</a>,&#8221; Stephen Weiss of Short Hills Capital Partners named TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) as<a href="https://www.benzinga.com/quote/TDG/analyst-ratings"> his final trade</a>.
On Monday, JPMorgan analyst Seth Seifman maintained TransDigm with a Neutral and raised the price target from $1435 to $1555.
Jenny Van Leeuwen Harrington of Gilman Hill Asset Management said Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) has a 7.5% dividend yield. Jefferies also upgraded the stock recently from Hold to Buy and raised the price target from $13 to $15, she added.
Easterly Government Properties will release its third quarter financial results on Nov. 5. Analysts expect the company to report quarterly earnings at 5 cents per share on revenue of $76.7 million.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Kari Firestone of Aureus Asset Management picked Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>).
On Oct. 10, Goldman Sachs analyst Gavin Parsons maintained Booz Allen Hamilton with a Buy and raised the price target from $174 to $196.
Joseph M. Terranova of Virtus Investment Partners named ONEOK, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) as his final trade.
On Wednesday, RBC Capital analyst Elvira Scotto maintained ONEOK with a Sector Perform rating and raised the price target from $89 to $98. The board of directors of ONEOK also declared a quarterly dividend of 99 cents per share, unchanged versus the previous quarter.
Price Action:
<ul>
<li>TransDigm Group fell 0.5% to close at $1,384.07 during Wednesday's session.</li>
<li>Easterly Government Properties shares rose 2.9% to settle at $14.35 on Wednesday.</li>
<li>Booz Allen Hamilton shares gained 1.1% to settle at $164.13 on Wednesday.</li>
<li>ONEOK shares gained 0.7% to close at $95.65.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Wikimedia Commons

Long Ideas

Media

TransDigm, Easterly Government Properties, Booz Allen Hamilton And An Energy Stock On CNBC's 'Final Trades'

CNBC Final Trades: TransDigm, Easterly Government Properties, Booz Allen Hamilton, Oneok

~ 100% leased, triple net asset with annual rent escalations ~
Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) (the "Company" or "Easterly"), a fully integrated real estate investment trust focused primarily on the acquisition, development and management of Class A commercial properties leased to the U.S. Government and its adjacent partners, announced today that it has acquired a 104,136 square foot facility 100% leased to Northrop Grumman Systems Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>, S&amp;amp, , P: BBB+)))), a multinational aerospace and defense company, located in Aurora, Colorado ("Northrop Grumman - Aurora").
The facility, developed in 2002, was built-to-suit for TRW Inc., an aerospace and automotive corporation acquired by Northrop Grumman in that same year. Approximately 70% of the three-floor buildout is constructed under secure design standards as required by the U.S. Government related to the tenant's contracts with Buckley Space Force Base ("Buckley SFB"). This secure space is certified and accredited as meeting Director of National Intelligence security standards for the processing, storage, and discussion of sensitive compartmented information.

Easterly Government Properties Acquires 104,136 SF Facility Adjacent To Buckley Space Force Base And Occupied By Northrop Grumman Systems Corporation; No Financial Terms Disclosed

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/63c6ba8b5750940001b7cb04/jake-roberge">William Blair analyst Jake Roberge</a> upgraded the rating for Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) from Market Perform to Outperform. Elastic shares gained 1.2% to close at $83.00 on Friday. <a href="https://www.benzinga.com/quote/ESTC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Rob Owens upgraded SentinelOne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/S#NYSE">S</a>) from Neutral to Overweight and raises the price target from $25 to $32. SentinelOne shares fell 0.5% to close at $25.71 on Friday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Daniel Rizzo upgraded AptarGroup, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATR#NYSE">ATR</a>) from Hold to Buy and raised the price target from $155 to $215. AptarGroup shares gained 1.5% to close at $161.55 on Friday. <a href="https://www.benzinga.com/quote/ATR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Evercore ISI Group analyst Chris McNally upgraded the rating for BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>) from In-Line to Outperform and boosted the price target from $39 to $43. BorgWarner shares gained 0.5% to close at $35.05 on Friday. <a href="https://www.benzinga.com/quote/BWA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies analyst Peter Abramowitz upgraded Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) from Hold to Buy and raised the price target from $13 to $15. Easterly Government Properties shares gained 0.8% to close at $13.27 on Friday. <a href="https://www.benzinga.com/quote/DEA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ESTC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="500" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14090802/image-98-1024x500.png" alt="" class="wp-image-593848" style="width:541px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14090802/image-98-1024x500.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14090802/image-98-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14090802/image-98-768x375.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/14090802/image-98.png 1361w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41308141/this-analyst-with-85-accuracy-rate-sees-around-20-upside-in-amd-here-are-5-stock-picks-for-last-week">This Analyst With 85% Accuracy Rate Sees Around 20% Upside In AMD &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Upgrades

ESTC

This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Jefferies analyst Peter Abramowitz upgrades Easterly Government Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>) from Hold to Buy and raises the price target from $13 to $15.

Jefferies Upgrades Easterly Government Props to Buy, Raises Price Target to $15

Top Democrats from influential House committees are urging the Drug Enforcement Administration (DEA) to expedite the process of <a href="https://www.benzinga.com/topic/cannabis-rescheduling">rescheduling cannabis.</a>
In a letter sent to Attorney General Merrick Garland and DEA Administrator Anne Milgram, Representatives Jerrold Nadler (D-NY) and Frank Pallone (D-NJ), ranking members of the Judiciary and Energy &amp; Commerce Committees respectively, stressed the need for quick action following a scientific review by the Biden administration.
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40938172/no-turning-back-now-cannabis-rescheduling-gains-momentum-expert-offers-timeline">&#8216;No Turning Back Now&#8217;: Cannabis Rescheduling Gains Momentum, Expert Offers Timeline</a>
According to <a href="https://www.marijuanamoment.net/top-congressional-democrats-push-dea-to-swiftly-reschedule-marijuana-and-continue-to-assess-full-legalization/">Marijuana Moment</a>, the lawmakers argue that cannabis has &#8220;less potential for abuse than other drugs&#8221; and serves an &#8220;accepted medical use in treatment.&#8221;
Their comments align with recommendations from the Department of Health and Human Services (HHS) and the Department of Justice, which have called for the reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).
&#8220;We value the Department of Justice's steadfast commitment to prevent the misuse and diversion of controlled substances that pose a threat to public health," Nadler and Pallone wrote.
The lawmakers applauded the Biden administration for initiating the review and urged the DEA to &#8220;swiftly complete this process and transfer marijuana to schedule III.&#8221;
<h3 class="wp-block-heading">Push For Full Descheduling</h3>
While the immediate focus is on rescheduling to Schedule III, which would loosen some federal restrictions on cannabis, the legislators also urged federal agencies to explore further reform. 
They said that &#8220;continuing to assess whether schedule IV, schedule V, or descheduling may be appropriate&#8221; could be the next step in aligning cannabis policy with evolving scientific and medical understanding. 
Descheduling, which would remove cannabis from the CSA entirely, remains a key objective for many advocates and lawmakers, including Nadler, who has previously sponsored the MORE Act &#8211; a bill that would result in full legalization.
<h3 class="wp-block-heading">Election-Year Focal Point</h3>
The timing of the lawmakers' push comes as cannabis policy increasingly takes center stage in <a href="https://www.benzinga.com/markets/cannabis/24/09/40785015/harris-campaign-accuses-trump-of-blatant-pandering-and-lying-about-his-cannabis-support-announce">U.S. election politics.</a> Both major parties are positioning themselves on the issue as the 2024 presidential election approaches. 
However, final action on the rescheduling is not expected until after November, with the DEA scheduling an administrative hearing on the matter for December 2. This hearing will allow for further input from experts and stakeholders before the agency potentially finalizes its decision.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/41015020/dea-boosts-psychedelics-production-for-research-cannabis-quotas-hold-steady-ahead-of-reschedulin">DEA Boosts Psychedelics Production For Research, Cannabis Quotas Hold Steady Ahead Of Rescheduling</a></li>
</ul>

Regulations

Politics

House Democrats Urge DEA To Speed Up Cannabis Rescheduling

Edwin Rubis has served 27 years of a 40-year federal prison sentence after being convicted on non-violent cannabis related charges in the late 1990s. Cannabis and criminal justice reform advocates are rallying for his release by way of a presidential pardon from the <a href="https://www.benzinga.com/topic/biden-administration">Biden Administration</a>.
Rubis, now 56, was 29 years old with one child and another on the way in 1998 when the DEA arrested him and charged him with conspiracy to distribute cannabis. No drugs, guns or money were found in Edwin&#8217;s possession. Still, he was found guilty and sentenced to 40 years.
In the 27 years he has served so far, Rubis has been an exemplary inmate earning three college degrees and completing 30+ rehabilitation programs. Without government intervention, his earliest release date is not until 2031 when he will be 63 years old.
&#8220;I no longer belong in prison. I am not a threat to society. The Bureau of Prisons has categorized me as a low non-violent offender for recidivism purposes. I am a non-violent cannabis offender. I believe in redemption," Rubis <a href="https://www.prnewswire.com/news-releases/who-is-edwin-rubis-getting-to-know-the-man-serving-a-40-year-sentence-for-non-violent-cannabis-charges---beard-bros-media-302245867.html">said</a> in a <a href="https://drupal-cloudfront.benzinga.com/topic/beard-bros-pharms-0">Beard Bros Pharm</a> press release. "I am a compassionate and relatable individual who does not judge others by their culture, creed, or religion, but by the intentions of their heart. I am honest and loyal; responsible and accountable. I deserve a second chance at life.&#8221;
His parents are in their 80s and Edwin wants to see them again. His three adult children have been deprived of their father&#8217;s presence for most of their lives, noted Beard Bros, a legacy brand and media outlet calling on President Joe Biden to grant a full pardon and release Rubis from federal prison.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40867166/federal-marshals-raid-legal-medical-marijuana-shop-in-texas-why-the-big-guns-advocates-say-its-a">Federal Marshals Raid Legal Medical Marijuana Shop In Texas: Why The Big Guns? Advocates Say &#8216;It&#8217;s Absurd&#8217;</a>
<h2 class="wp-block-heading">Biden&#8217;s Unfulfilled Promise </h2>
October 6, 2022, <a href="https://www.benzinga.com/markets/cannabis/22/10/29175510/breaking-biden-announces-pardons-for-all-federal-marijuana-possession-convictions">Biden issued a general pardon </a>for previous crimes of simple cannabis possession in violation of federal law and the D.C. Code. In December 2023,<a href="https://www.benzinga.com/markets/cannabis/23/12/36361671/biden-pardons-thousands-convicted-of-cannabis-possession-calls-on-governors-to-do-the-same"> Biden expanded the pardon</a> to cover offenses for cannabis use and simple possession and called on state governors to do the same. 
Still nothing: There have been no pardons for federal inmates doing time for non-violent cannabis crimes. Beard Bros Pharm points out that Rubis "is not the only prisoner who fits that description but his continued incarceration is a reminder of the half-steps taken by this administration when it comes to cannabis reform and his immediate release would signal the Democratic Party&#8217;s commitment to future criminal justice reform."
Since he is not seeking re-election, President Biden has just over two months until Election Day and over four months until a new president is sworn in, "to right what he calls ‘historic wrongs&#8221; and grant Edwin Rubis a full presidential pardon.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40846480/cannabis-experts-say-weed-reform-is-a-race-against-time-is-the-dea-delaying-bidens-rescheduling-">Cannabis Experts Say Weed Reform Is A Race Against Time, Is The DEA Delaying Biden&#8217;s Rescheduling Proposal?</a></li>
</ul>
Photo courtesy of Last Prisoner Project

Government

Meet The Man Serving A 40-Year Sentence For Non-Violent Cannabis Charges, Awaiting Pardon From Biden

Investors in the cannabis sector are closely watching the potential rescheduling of cannabis by the DEA—a decision that could reshape the industry and unlock significant tax relief. As experts at a recent webinar discussed, the path forward hinges on a key Administrative Law Judge (ALJ) hearing scheduled for December 2, 2024, which could determine how quickly these changes will come and how much the market might shift.
<h3 class="wp-block-heading">Why Cannabis Reform Is Not A Priority In 2024</h3>
On September 11, 2024, Zuanic &amp; Associates hosted a comprehensive webinar focused on the ongoing process of cannabis rescheduling in the United States. Moderated by senior analyst <a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic</a> and Anthony Coniglio, CEO of (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NLCP#OTC">NLCP</a>), the panel featured industry experts Kelly Fair, a partner at Dentons, and Morgan Fox, the political director of the National Organization for the Reform of Marijuana Laws (NORML), the oldest cannabis reform organization in the U.S., founded in 1970.
Both panelists highlighted that while cannabis policy reform has gained traction among presidential candidates, it remains a secondary issue for the majority of voters.
Fox emphasized that although <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38905962/cannabis-rescheduling-when-will-it-happen-expert-lays-out-timeline-risks-and-wild-c">rescheduling</a> is a step in the right direction, NORML's ultimate goal is <a href="https://www.benzinga.com/markets/cannabis/23/04/31779376/exclusive-deschedulingrescheduling-cannabis-will-it-be-an-expeditious-path-to-280e-relief-this-i">full descheduling</a>. Fox suggested that descheduling would allow Congress to take meaningful steps toward regulating cannabis effectively, unlike the rescheduling process, which he deemed prone to political delays.
Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.
<h3 class="wp-block-heading">Who Gets To Speak At The Cannabis Hearing?</h3>
A significant portion of the discussion revolved around the technical aspects of the upcoming ALJ hearing. Fair clarified the procedural steps, noting that those wishing to speak must apply by September 30 with final speaker lists expected by November 2024.
Fair highlighted the importance of this hearing in shaping the final rescheduling rule, as it provides a platform for both proponents and opponents of the rescheduling proposal to present evidence. However, the panel agreed that the DEA retains substantial discretion in deciding the scope of the hearing and final rule.
Evidence and expert testimony presented during the<a href="https://www.benzinga.com/markets/cannabis/24/06/39436068/dea-18-gop-state-attorneys-general-want-public-hearing-on-cannabis-rescheduling-as-deadline-loom"> ALJ hearing</a> will play a pivotal role in shaping the DEA&#8217;s final decision on cannabis rescheduling. Both proponents and opponents of rescheduling will need to provide compelling arguments, as the DEA&#8217;s interpretation of this evidence could determine the outcome of the entire process.
<h3 class="wp-block-heading">Potential Delays And Challenges</h3>
Both Fox and Fair acknowledged that procedural hurdles and potential judicial challenges could prolong the timeline. Fox noted that any final ruling would likely face legal opposition, which could further <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40580306/cannabis-stocks-plummet-by-up-to-16-on-dea-rescheduling-delay-could-this-be-the-buy">delay implementation</a>. Fair added that while the ALJ's findings are essential, the DEA is not obligated to follow those recommendations, which adds another layer of uncertainty.
The webinar concluded with cautious optimism.
While rescheduling could provide some immediate relief, particularly by eliminating the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/08/33482140/rescheduling-cannabis-what-are-the-implications-for-msos-tax-rule-280e-fda-and-phar">280E tax burden</a>, the path forward remains uncertain due to potential political changes and judicial challenges. The panelists agreed that rescheduling is a step in the right direction but emphasized that descheduling remains the ultimate goal for meaningful cannabis reform.
Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40712816/what-trump-learned-about-marijuana-that-desantis-did-not-and-why-the-gop-might-become-weed-frien">What Trump Learned About Marijuana That DeSantis Did Not And Why The GOP Might Become Weed-Friendly</a>

Exclusives

NLCP

Cannabis Experts Say Weed Reform Is A Race Against Time, Is The DEA Delaying Biden's Rescheduling Proposal?

MMJ BioPharma Cultivation finds itself at the center of a pivotal legal struggle with the Drug Enforcement Administration (DEA), accusing the agency of significant delays in processing its application to grow marijuana for pharmaceutical research. The company's<a href="https://www.benzinga.com/markets/cannabis/24/04/38182443/this-is-insanity-someones-got-to-act-marijuana-researcher-files-fed-lawsuit-against-dea-over-unc"> lawsuit</a> claims these delays have hindered critical clinical trials aimed at developing treatments for debilitating conditions such as Multiple Sclerosis (MS) and Huntington's Disease (HD), thereby prolonging the suffering of patients who could benefit from <a href="http://benzinga.com/topic/medical-cannabis">cannabis-based</a> therapies.
<h3 class="wp-block-heading">MMJ Struggles With DEA Delays</h3>
Duane Boise, president and CEO of MMJ International Holdings, explained to Benzinga that these delays have severely impacted the company's ability to cultivate the specific cannabis strains needed to produce active pharmaceutical ingredients (APIs). "Because the DEA has significantly delayed our DEA registration, MMJ has not been able to grow the specific marijuana plant cultivars utilized in the development of our API. There is currently no one in the United States growing specific cultivars to MMJ's pharmaceutical specifications," Boise noted. Even if MMJ could source these cultivars from other countries, it would still face roadblocks, as the company lacks the necessary DEA registration to process them within the U.S.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Investments And Clinical Trials Stalled By Federal Obstacles</h3>
The delays have not only impacted research but also deterred investors. "We have had investors ready to invest but when they saw the DEA roadblocks, it delayed the investment, thus extending the research timelines," Boise added. Despite these challenges, MMJ has successfully developed a soft gelatin capsule, <a href="https://www.benzinga.com/general/biotech/23/09/34770215/cannabis-research-company-submits-fda-responses-for-gel-capsule-approval">which is awaiting FDA approval</a>. Once approved, it will be used in human clinical trials, but for now, the company's research is in limbo.
Boise also addressed the Department of Justice&#8217;s (DOJ) argument that MMJ's lawsuit lacks subject-matter jurisdiction, explaining that the DEA has already conducted and completed its investigation in Rhode Island, where MMJ holds the required licenses. He contends that the DOJ's claim is a diversion tactic meant to confuse the court.
<h3 class="wp-block-heading">Constitutional Issues Raised In MMJ Case</h3>
MMJ's legal case <a href="https://www.accesswire.com/915174/mmj-biopharma-vs-dea-the-marijuana-rescheduling-scam-unveiled-a-defining-battle-for-federal-cannabis-reform-and-medical-research">raises</a> broader constitutional questions, particularly concerning the use of the Administrative Law Judges (ALJs) process used by the DEA in enforcement actions. Boise described the ALJ process as inherently biased: "When the Administrative Law Judge is judge, jury, and executioner how can this be impartial? The judge is blocking MMJ from questioning key DEA employees,&#8221; he remarked. Boise further emphasized that despite the <a href="https://www.benzinga.com/markets/cannabis/22/12/29944802/breaking-biden-signs-marijuana-research-bill-historic-moment-for-federal-cannabis-reform">marijuana research act</a>, which mandates a 90-day timeline for approval or denial, the judge has consistently failed to address the significant delays.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40823104/cannabis-companies-fight-federal-court-dismissal-on-prohibition-lawsuit-heading-to-next-legal-st">Cannabis Companies Fight Federal Court Dismissal On Prohibition Lawsuit, Heading To Next Legal Stop</a>
Moreover, MMJ BioPharma's legal position was bolstered by the <a href="https://www.benzinga.com/markets/cannabis/24/07/39598920/supreme-court-ruling-will-help-this-companys-battle-against-deas-kangaroo-court-and-anti-cannabi">recent Supreme Court ruling in Jarkesy v. SEC</a>, which reaffirmed the right to a jury trial in cases involving federal agency enforcement. Boise sees this ruling as a critical turning point. "A fair impartial trial will not take place unless the court abides by the recent Supreme Court ruling &#8211; Chevron Deference. Ambiguity in the law is not for the interpretation of the DEA, however, the truth is, and having a federal court recognize the truth is the end game."
<h3 class="wp-block-heading">MMJ BioPharma Committed To Long-Term Fight</h3>
Although these delays have altered MMJ's timeline, Boise made it clear that the company is in this fight for the long haul. "Yes, it has delayed our implementation by five years. We are prepared for the long haul and will maintain and persevere until the government decides to act in accordance with the law," he said. MMJ says it hopes the outcome of this case will set a precedent for both cannabis research and federal cannabis policy. "The DEA cannot continue to keep moving the goal post by their biased interpretations," Boise concluded.
The outcome of MMJ BioPharma's lawsuit could have far-reaching implications not just for the company's research, but for the broader <a href="http://benzinga.com/cannabis">cannabis industry</a>, especially as the <a href="https://www.benzinga.com/topic/cannabis-rescheduling">DEA's rescheduling</a> efforts progress.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/09/40804308/will-the-dea-complete-cannabis-rescheduling-hear-from-experts-the-day-after-harris-trump-debate">Will The DEA Complete Cannabis Rescheduling? Hear From Experts The Day After Harris-Trump Debate</a></li>
</ul>
Featured image generated with AI tools.

Interview

EXCLUSIVE: DEA Stalling Hinders Critical Clinical Trials For Debilitating Conditions, Says MMJ BioPharma CEO

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Easterly Government Properties, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEA#NYSE">DEA</a>)</h3>
<ul>
<li>Dividend Yield: 7.99%</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and raised the price target from $13 to $14 on Aug. 29. This analyst has an accuracy rate of 70%.</li>
<li>RBC Capital analyst Michael Carroll downgraded the stock from Sector Perform to Underperform and cut the price target from $15 to $13 on Aug. 16, 2023. This analyst has an accuracy rate of 64%.</li>
<li>Recent News: On Sept. 5, Easterly Government Properties acquired 99,246 SF 100% leased to Northrop Grumman Systems.</li>
<li>Benzinga Pro's real-time newsfeed alerted to<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1"> latest DEA news. </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="908" height="838" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070147/image-97.png" alt="" class="wp-image-544247" style="width:714px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070147/image-97.png 908w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070147/image-97-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070147/image-97-768x709.png 768w" sizes="(max-width: 908px) 100vw, 908px" /></a></figure>
<h3 class="wp-block-heading">Clipper Realty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLPR#NYSE">CLPR</a>)</h3>
<ul>
<li>Dividend Yield: 7.44%</li>
<li>Raymond James analyst Buck Horne downgraded the stock from Outperform to Underperform on April 15. This analyst has an accuracy rate of 74%.</li>
<li>JMP Securities analyst Aaron Hecht downgraded the stock from Market Outperform to Market Perform on April 11. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On Aug. 1, Clipper Realty reported better-than-expected second-quarter revenue and FFO results.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1"> trend in CLPR stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="918" height="846" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070228/image-98.png" alt="" class="wp-image-544248" style="width:641px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070228/image-98.png 918w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070228/image-98-300x276.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12070228/image-98-768x708.png 768w" sizes="(max-width: 918px) 100vw, 918px" /></a></figure>
<h3 class="wp-block-heading">Park Hotels &amp; Resorts Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>)</h3>
<ul>
<li>Dividend Yield: 7.32%</li>
<li>Truist Securities analyst Patrick Scholes maintained a Buy rating and cut the price target from $20 to $18 on Sept. 4. This analyst has an accuracy rate of 70%.</li>
<li>UBS analyst Robin Farley maintained a Neutral rating and cut the price target from $18 to $14 on Aug. 16. This analyst has an accuracy rate of 84%.</li>
<li>Recent News: On July 31, Park Hotels &amp; Resorts posted weak quarterly sales.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1">breakout in PK shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent091224&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="867" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12071539/image-1-27.png" alt="" class="wp-image-544263" style="width:649px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12071539/image-1-27.png 867w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12071539/image-1-27-300x288.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/12071539/image-1-27-768x736.png 768w" sizes="(max-width: 867px) 100vw, 867px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/09/40813043/jim-cramer-not-the-time-to-own-oil-when-asked-about-exxon-mobil-says-ibm-is-performing-well">Jim Cramer: &#8216;Not The Time To Own Oil,&#8217; When Asked About Exxon Mobil; Says IBM Is &#8216;Performing Well&#8217;</a></li>
</ul>

Wall Street's Most Accurate Analysts Spotlight On 3 Real Estate Stocks With Over 7% Dividend Yields

One day after the September Tuesday&#8217;s presidential debate, industry experts will break down the cannabis rescheduling process, a crucial issue for investors. Equity research firm Z&amp;A is hosting a <a href="https://zoom.us/webinar/register/WN_Jp3YHP7MSJGEeKrf2cL1eA#/registration">webinar</a> on Wednesday at 4:20 PM ET to provide insights into the upcoming regulatory shifts and market implications.
Get Benzinga's exclusive analysis and top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.
<h3 class="wp-block-heading">DEA's Rescheduling Process</h3>
The conversation comes at a pivotal moment following the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39912859/as-election-buzz-swirls-around-biden-and-harris-dea-comment-period-ends-whats-next-">end of the public comment period</a> for the DEA to reschedule cannabis from Schedule I to Schedule III. Proposed by the Department of Justice on May 21 2024, the move was met with positive responses, as <a href="https://www.benzinga.com/markets/cannabis/24/05/39011156/exclusive-we-analyzed-4-000-dea-marijuana-rescheduling-comments-heres-what-americans-really-thin">75.9% of over 4,000 public comments </a>analyzed by Benzinga Cannabis showed support for rescheduling, mainly due to the medical benefits and alignment with state laws.
<h3 class="wp-block-heading">DEA Rescheduling Delay</h3>
On August 27, 2024, the DEA announced a delay in its final ruling until after the November election.
This triggered sharp declines in cannabis stocks, with the AdvisorShares Pure US Cannabis ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSOS#NYSE">MSOS</a>) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40580306/cannabis-stocks-plummet-by-up-to-16-on-dea-rescheduling-delay-could-this-be-the-buy">dropping over 10%</a>. Major players like Curaleaf Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>), Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>), and Cansortium (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CNTMF#OTC">CNTMF</a>) saw stock prices plunge by as much as 16%.
<h3 class="wp-block-heading">Investor's Angle: Upcoming Panel Post-Debate Chaos</h3>
If cannabis is reclassified, the industry could see significant changes such as tax reforms, enhanced research opportunities and the development of new regulatory frameworks.
This is where the insights from experts like Kelly Fair and Morgan Fox become crucial. Fair, a partner at Dentons, specializes in regulatory compliance and corporate governance within the cannabis sector. With nearly two decades of experience, she will provide in-depth perspectives on the technical aspects of the rescheduling process, the role of the DEA and possible legal outcomes. 
Meanwhile, Fox, the political director at NORML, will focus on the political landscape. With over 15 years of experience in cannabis policy reform, Fox will explain why descheduling remains the ultimate goal and how rescheduling fits into the bigger picture of cannabis reform.
Co-hosted by senior analyst <a href="https://www.benzinga.com/topic/pablo-zuanic">Pablo Zuanic </a>from Zuanic &amp; Associates, and Anthony Coniglio, CEO of NewLake Capital Partners (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NLCP#OTC">NLCP</a>), <a href="https://zoom.us/webinar/register/WN_Jp3YHP7MSJGEeKrf2cL1eA#/registration">the panel</a> promises to shed light on the future of cannabis regulation, particularly in light of the September 10th presidential debate.
Read Next:<a href="https://www.benzinga.com/markets/cannabis/24/09/40782415/top-dem-congressman-calls-trumps-cannabis-support-a-powerful-signal-to-gop-when-even-donald-trum"> Top Dem Congressman Calls Trump&#8217;s Cannabis Support A &#8216;Powerful Signal&#8217; To GOP: &#8216;When Even Donald Trump Can Get On Board…&#8217;</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Z&amp;A SPACES ON S3 RESCHEDULING: Dentons' Kelly Fair and NORML's Morgan Fox will discuss the technical and political aspects of S3 Rescheduling &amp; future developments (bifurcation? MMJ legalization? De-scheduling? Z&amp;A's <a href="https://twitter.com/420Odysseus?ref_src=twsrc%5Etfw">@420Odysseus</a> &amp; NLCP's <a href="https://twitter.com/AnthonyConigli0?ref_src=twsrc%5Etfw">@AnthonyConigli0</a> will host (Wed Sep 11 @… <a href="https://t.co/iMLzlfsIyE">pic.twitter.com/iMLzlfsIyE</a>
&mdash; Pablo Zuanic (@420Odysseus) <a href="https://twitter.com/420Odysseus/status/1832508687102951850?ref_src=twsrc%5Etfw">September 7, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>

CNTMF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

MSOS

Will The DEA Complete Cannabis Rescheduling? Hear From Experts The Day After Harris-Trump Debate

An U.S. appeals court has ruled that THC-O-acetate, a hemp-derived cannabinoid, is federally legal under the&nbsp;2018 Farm Bill. 
This ruling contradicts the position of the&nbsp;Drug Enforcement Administration (DEA) on legal cannabinoids, which had classified THC-O as a Schedule I controlled substance, <a href="https://www.marijuanamoment.net/thc-o-qualifies-as-legal-hemp-under-federal-law-appeals-court-says-rejecting-deas-restrictive-stance/">reported</a> Marijuana Moment.
The decision comes from the U.S. Court of Appeals for the Fourth Circuit.
<h3 class="wp-block-heading">The Case And Ruling</h3>
The case, which involved an employment dispute, hinged in part on the legal status of THC-O. A majority of the three-judge panel ruled that the <a href="https://www.benzinga.com/markets/cannabis/24/05/39046889/dea-rules-thca-is-not-legal-hemp-amid-industry-shake-up-and-farm-bill-debate-on-delta-8-thc-proh">DEA's interpretation </a>of the Farm Bill was too restrictive, saying that it does not apply to THC-O, a compound synthesized from legal hemp cannabinoids.
This decision builds on earlier rulings, particularly from the <a href="https://www.benzinga.com/markets/cannabis/23/10/35053162/court-orders-dea-to-respond-to-medical-marijuana-companys-request-for-bulk-manufacturing-registr">Ninth Circuit Court of Appeals</a>, which has previously ruled that cannabinoids like delta-8 THC are legal under the Farm Bill.
In its decision, the Fourth Circuit panel <a href="https://www.ca4.uscourts.gov/opinions/231400.P.pdf">wrote</a>, 
&#8220;The DEA's February 2023 letter clarified that THC-O doesn't occur naturally in the cannabis plant and can only be obtained synthetically, and therefore does not fall under the definition of hemp. However, the court found this interpretation overly restrictive and concluded that synthetically derived cannabinoids could still qualify as hemp under the 2018 Farm Bill if they contain less than 0.3 percent delta-9 THC.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40740888/missouris-hemp-battle-heats-up-as-governor-parson-revives-ban-in-a-mark-twain-like-drama">Missouri&#8217;s Hemp Battle Heats Up As Governor Parson Revives Ban In A Mark Twain-Like Drama</a>
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Federally Legal Cannabinoid</h3>
The judges emphasized their agreement with the Ninth Circuit's interpretation of the 2018 Farm Act, stating that the federal definition of hemp is clear and unambiguous. 
&#8220;We reject [the employer's] contention that the DEA's interim final rule mandates a finding that THC-O is illegal, agreeing instead with the Ninth Circuit's interpretation that products containing less than 0.3 percent delta-9 THC qualify as legal hemp regardless of whether they are synthetically derived,&#8221; ruled the judges.
Therefore, the ruling effectively counters the <a href="https://www.benzinga.com/markets/cannabis/23/02/30885046/delta-8-9-remains-a-controlled-substance-despite-hemp-bill-dea">DEA's February 2023</a> letter, which aimed to classify THC-O as illegal under federal law. The ruling might have broader implications for other cannabinoids, such as THCA.
If you&#8217;re interested in diving deeper into the consequences of the ongoing dispute between the cannabis and hemp THC industries, you might enjoy reading Benzinga&#8217;s series of <a href="https://www.benzinga.com/topic/hemp" target="_blank" rel="noreferrer noopener">articles</a> on the matter. We invite you to dive in!
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/09/40698576/navigating-hemp-vs-cannabis-debate-one-agenda-for-all-us-cannabis-councils-david-culver-weighs-i">Navigating Hemp Vs. Cannabis Debate: One Agenda For All? US Cannabis Council&#8217;s David Culver Weighs In</a></li>
</ul>
<h3 class="wp-block-heading"></h3>

U.S. Court Says This Cannabinoid Is Legal, Rejects DEA's Position On Controlled Substances

Real Estate

Easterly Government Properties Acquires 99,246 SF 100% Leased To Northrop Grumman Systems

The Mississippi State Legislature passed legislation Tuesday to establish the Mississippi Medical Cannabis Research Program at the University of Mississippi, marking a significant step forward in the study of <a href="http://benzinga.com/topic/medical-cannabis">medical marijuana</a> applications. Governor Tate Reeves (R) ratified the bill, which aims to deepen understanding of cannabis&#8217;s therapeutic potential and its impact on patient care.
<h3 class="wp-block-heading">Bipartisan Effort Supports Ole Miss's Legacy In Cannabis Research</h3>
Spearheaded by State Senator Kevin Blackwell (R) and co-authored by State Senators Reginald Jackson (D), Rod Hickman (D), Sarita Simmons (D) and Nicole Boyd (R), this initiative seeks to leverage Ole Miss&#8217;s longstanding expertise as a premier research institution. Historically, the University of Mississippi was the sole federally authorized cannabis cultivation site for research since 1968, a distinction that held until 2022 when the Drug Enforcement Administration (DEA) <a href="https://www.benzinga.com/markets/cannabis/22/01/24909785/dea-ends-5-decade-federal-monopoly-on-research-cannabis-production-approves-two-companies-to-har">authorized additional growers for research</a>.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter<a href="https://newsletteremail.benzinga.com/subscribe"> here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
&#8220;We are grateful for the leadership of Gov. Reeves and the tireless efforts of Sen. Blackwell, Sen. Boyd and their colleagues in championing this landmark legislation,&#8221; <a href="https://olemiss.edu/news/2024/09/medical-cannabis-research-program/index.html">said</a> Robert Welch, director of the university's National Center for Cannabis Research and Education (NCCRE) in a press release.
<h3 class="wp-block-heading">Bridging Cannabis Research With Health Policies</h3>
The program, housed in the university&#8217;s School of Pharmacy, will operate under the aegis of the newly established <a href="https://olemiss.edu/departments/pharmacy/national-cannabis-center/">NCCRE</a>. It will collaborate closely with the Mississippi Department of Health&#8217;s Mississippi Medical Cannabis Program and various patient advocacy groups to disseminate findings that are comprehensible to healthcare providers, patients, caregivers, law enforcement and policymakers.
<h3 class="wp-block-heading">Bill Secures Funding For Cannabis Research</h3>
The <a href="https://billstatus.ls.state.ms.us/2024/pdf/history/SB/SB2888.xml">bill</a> outlines the creation of an advisory board to oversee research compliance and strategic direction and provides the necessary funding to support scientific investigations. This funding is a pivotal component for exploring new therapeutic potentials and <a href="https://www.benzinga.com/topic/cannabis-education">educational initiatives</a> surrounding medical cannabis.
&#8220;The National Center for Cannabis Research and Education will help to ensure that Mississippi remains at the forefront of natural products research,&#8221; noted Senator Boyd. &#8220;I am proud of the University of Mississippi for continuing to be a national leader in research excellence.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/07/39983822/cannabis-educational-content-should-be-incorporated-into-curricula-at-all-levels-says-american-c">Cannabis Educational Content Should Be Incorporated Into Curricula At All Levels, Says American College Of Physicians</a></li>
</ul>
Photo by Kevin Bain/Ole Miss Digital Imaging Services.

Education

Health Care

Cannabis Research Program At Ole Miss Approved, Funded By Mississippi Legislature

Editor&#8217;s note: this article has been updated to reflect the views of the NCR more accurately.
The U.S. Drug Enforcement Administration (DEA) has scheduled a hearing on Dec. 2, 2024, to discuss the proposed <a href="https://www.benzinga.com/markets/cannabis/24/08/40613739/dea-schedules-hearing-on-proposed-ban-of-psychedelics-doi-doc-amid-researchers-concerns">reclassification of cannabis as a Schedule III substance</a> under the Controlled Substances Act. This marks a crucial step in the ongoing process of cannabis rescheduling, drawing attention from industry leaders and stakeholders.
Saphira Galoob, executive director of the National Cannabis Roundtable (NCR) and upcoming speaker at the <a href="https://www.benzinga.com/events/cannabis-conference/">Benzinga Cannabis Capital Conference</a>, issued a press release sharing the organization's position on the hearing, emphasizing the importance of utilizing every aspect of the administrative process.
"For significant decisions, it is only logical that all pieces of the administrative process are utilized, and a hearing reflects the gravity of change that accompanies reversing decades of misguided federal drug policy," she said.
The Role of Science and Public Opinion
Galoob highlighted the overwhelming support for moving cannabis to Schedule III. Tens of thousands of individuals and organizations have submitted comments in favor of the change, she noted.
Scientific and medical analyses conducted by federal health agencies, including the FDA and NIDA, have recognized the accepted medical use of cannabis. "We will continue to stand in strong support of the medical and science-driven analyses by multiple federal health agencies," Galoob affirmed.
Implications of Rescheduling
The rescheduling of cannabis has been a long-standing issue within the industry, with many advocating for its removal from Schedule I, where it currently sits alongside substances like heroin. Moving cannabis to Schedule III would acknowledge its medical benefits and potentially ease some of the restrictions that have hindered research and industry growth.
Galoob reiterated the NCR&#8217;s commitment to supporting the rescheduling effort and countering misinformation. "We look forward to the opportunity to participate in a hearing to speak in strong support of these conclusions… and to combat the misinformation being put forward by those who continue to ignore the science and data on cannabis," she stated.
<hr class="wp-block-separator has-alpha-channel-opacity" />
Cannabis rescheduling seems to be right around the corner. Want to understand what this means for the future of the industry? Hear directly for top executives, investors and policymakers at the&nbsp;19th Benzinga Cannabis Capital Conference,&nbsp;coming to Chicago this Oct. 8-9.&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">Get your tickets now</a>&nbsp;before prices surge by following&nbsp;<a href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" target="_blank" rel="noreferrer noopener">this link</a>.
Photo: Courtesy of geralt, lindsayfox Pixabay

Events

Cannabis Rescheduling Could Reverse 'Decades Of Misguided Drug Policy,' Says Key Industry Organization Following DEA Hearing Rescheduling (UPDATED)

The <a href="https://www.benzinga.com/markets/cannabis/23/12/36268778/matthew-perry-died-of-acute-effects-of-ketamine-medical-examiner-reports">death of &#8220;Friends&#8221; actor Matthew Perry</a> has spurred the <a href="https://www.benzinga.com/topic/drug-enforcement-administration">Drug Enforcement Administration (DEA)</a> into action. The agency is drawing alarming parallels between the rise in ketamine use and the early days of the opioid epidemic. As Double Blind <a href="https://doubleblindmag.com/dea-cracking-down-on-ketamine/">reported</a>, the DEA is now signaling a potential crackdown on what it describes as &#8220;ketamine pill mills,&#8221; sparking a heated debate within the medical and psychedelic communities.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40401735/matthew-perry-charges-filed-against-multiple-suspects-in-ketamine-overdose-death-of-friends-star">Matthew Perry&#8217;s Assistant, Doctors Charged With Supplying Ketamine To &#8216;Friends&#8217; Star, Aiding In Overdose Death (UPDATED)</a>
<h3 class="wp-block-heading">Rise Of Ketamine In Medicine And Popular Culture</h3>
In a recent statement, DEA Administrator Anne Milgram expressed concern over the increasing availability of <a href="https://www.benzinga.com/topic/ketamine">ketamine</a>, a drug that has traditionally not been at the forefront of the drug war. &#8220;Every single day, we are targeting and investigating doctors, nurse practitioners, others, who are violating this duty of trust to their patients by overprescribing medicine or prescribing medicine that isn't necessary,&#8221; Milgram <a href="https://www.cbsnews.com/video/deas-anne-milgram-compares-ketamine-abuse-with-beginning-of-opioid-epidemic/">told</a> CBS. The DEA&#8217;s investigation revealed that Matthew Perry was charged around $50,000 over one month for a supply of ketamine, raising red flags about potential overprescription practices.
Ketamine, once relegated to the realm of anesthetics and illicit use, has seen a resurgence in recent years as a promising treatment for depression, anxiety and <a href="https://www.benzinga.com/topic/ptsd">PTSD</a>. Johnson &amp; Johnson&#8217;s <a href="https://www.benzinga.com/markets/cannabis/24/07/39913847/pharma-giant-johnson-johnson-asks-fda-to-approve-esketamine-nasal-spray-for-treatment-resistant-">Spravato</a>, a ketamine-based nasal spray, is poised to become the first billion-dollar psychedelic treatment, reflecting the drug&#8217;s growing prominence in both medical and popular culture.
<h3 class="wp-block-heading">Concerns From Mental Health Professionals</h3>
However, the DEA&#8217;s focus on ketamine has sparked concern among mental health professionals and advocates who fear that the agency&#8217;s actions could stifle access to a potentially life-saving treatment. Sandhya Prashad, MD, president of the Association of Ketamine Physicians, Psychotherapists and Practitioners, emphasized the drug&#8217;s importance in psychiatry. &#8220;Further regulation and guardrails are certainly required. However, it is important to understand that ketamine is the only anti-suicidal / immediately lifesaving treatment within psychiatry currently that is also backed by well-conducted, rigorous trials from major academic institutions, and is a major advancement in a field where other treatments have a very low rate of response,&#8221; Prashad stated in the Ecstatic Integration newsletter.
The DEA&#8217;s rhetoric has also drawn criticism for its apparent echoes of the opioid crisis, particularly in its use of terms like &#8220;pill mills&#8221; to describe clinics that provide ketamine treatments. Ben Spielberg, CEO of Bespoke Treatment, acknowledged the need for better screening at ketamine clinics but warned against demonizing a drug that could offer significant benefits. &#8220;I personally have called 8 different ketamine clinics under a different name, and not a single one asked about my substance abuse history. Don't you think that would be among the most important questions asked?&#8221; Spielberg said. He stressed that while ketamine should not be used as a long-term treatment, it can play a crucial role in helping patients recover.
<h3 class="wp-block-heading">Elijah McClain&#8217;s Death: A Cautionary Tale</h3>
The debate over ketamine&#8217;s place in medicine took a darker turn following the death of Elijah McClain in 2019. McClain, who was <a href="https://www.benzinga.com/markets/cannabis/22/09/29023716/amended-autopsy-finds-elijah-mcclain-died-from-ketamine-injected-by-paramedics-called-by-cops">forcibly administered a large dose of</a> ketamine by paramedics after being detained by police, died under circumstances that have raised serious questions about the drug&#8217;s use outside of controlled clinical settings. While McClain&#8217;s case is markedly different from Perry&#8217;s, it underscores the potential dangers of ketamine when used improperly.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/03/37440649/paramedic-sentenced-to-5-years-in-ketamine-death-of-elijah-mcclain-judge-says-it-is-impossible-t">Paramedic Sentenced To 5 Years In Ketamine Death Of Elijah McClain, Judge Says &#8216;It Is Impossible To Unremember&#8217; Video Of His Suffering</a></li>
</ul>
Cover image made with AI

Psychedelics

DEA Warns Of Crackdown On Ketamine Prescribing Following Matthew Perry's Death

Easterly Government declares $0.265 dividend

Easterly Government Q3 Earnings Preview

Return To Sender: Sell Postal Realty Trust

Here's the major earnings before the open tomorrow

Easterly Government GAAP EPS of $0.05

06:40 EST Easterly Government Properties (DEA) sees 2024 core FFO $1.15-$1.17, consensus $1.15 Published first on TheFly – the ultimate source for ...

Easterly Government Properties sees 2024 core FFO $1.15-$1.17, consensus $1.15

06:41 EST Easterly Government Properties (DEA) sees 2025 core FFO $1.17-$1.21, consensus $1.17 Published first on TheFly – the ultimate source for ...

Easterly Government Properties sees 2025 core FFO $1.17-$1.21, consensus $1.17

John Kim, an analyst from BMO Capital, maintained the Sell rating on Easterly Government Properties (DEA – Research Report). The associated price t...

Easterly Government Properties: High Leverage and Payout Ratio Overshadow Positive Q3 2024 Results, Leading to Sell Rating

Easterly Government Properties Q3 earnings beat, introduces robust '25 guidance

Easterly Government Properties, Inc. (DEA) Q3 2024 Earnings Call Transcript

ACDC

AGCO

APLS

ARCH

BEAM

BLDP

BLDR

BRKR

CEIX

CNSL

DHLGY

DNNGY

ENDPQ

EXPD

GLDD

GOGO

HSIC

INGR

KPTI

LGIH

MITT

MLCO

MPLX

NMRK

ONIT

OXSQ

PAYO

PMTS

PSTL

PTLO

RACE

SHIP

SNDL

SQNS

TCNNF

TRGP

USAC

VWDRY

WLKP

Avenue Z Promotes Nneka Etoniru to Executive Vice President of Global Brand Strategy

Press Releases

Easterly Government Properties Reports Second Quarter 2024 Results

Easterly Government Properties to Participate in NYSE Real Estate Investor Access Day

Easterly Government Properties Completes Acquisition of VA - Jacksonville, the Final Acquisition of the 10 Properties in the VA Portfolio

Easterly Government Properties Acquires 99,246 SF Facility Adjacent to Wright-Patterson Air Force Base and Occupied by Northrop Grumman Systems Corporation

Management

Aligned Data Centers Appoints Meghan Baivier as Chief Financial Officer

Easterly Government Properties Acquires 104,136 SF Facility Adjacent to Buckley Space Force Base and Occupied by Northrop Grumman Systems Corporation

Easterly Government Properties Schedules Third Quarter 2024 Earnings Release and Conference Call

Comments

Easterly Government Props

Vendite allo scoperto

Easterly Government Props (NYSE:DEA) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO